A clinical investigation published in Artery Research identifies a specific long non-coding RNA, designated lncRNA ITGA2, as a potential blood-based biomarker for both the diagnosis of acute ischemic stroke and the prediction of post-stroke cognitive impairment. The study, conducted by a team of researchers including Lin Chen and Limin Yan, analyzed peripheral blood samples from 152 healthy individuals and 155 patients with confirmed acute ischemic stroke. The findings suggest that elevated levels of this RNA molecule in the blood are strongly associated with greater neurological severity and a significantly higher risk of developing cognitive deficits in the months following a stroke event.
Post-stroke cognitive impairment is a prevalent and debilitating consequence of ischemic stroke, affecting nearly half of survivors and ranging from mild cognitive deficits to vascular dementia. Current diagnostic methods for this condition typically rely on neuropsychological evaluations conducted weeks or months after the initial stroke, which delays early intervention and prevention strategies. While magnetic resonance imaging can reveal brain injury, its utility in predicting long-term cognitive outcomes is limited by moderate sensitivity and specificity, high costs, and the impracticality of repeated use. Consequently, there is a clinical need for objective, accessible biomarkers that can be applied during the acute phase to improve early detection and risk stratification.
Long non-coding RNAs have emerged as key epigenetic regulators in cerebrovascular diseases, exhibiting dynamic expression changes and involvement in mechanisms such as neuroinflammation, vascular remodeling, and synaptic plasticity. LncRNA ITGA2 has previously drawn interest in vascular biology due to its role in regulating vascular smooth muscle cell proliferation and migration. However, its specific contribution to post-stroke cognitive impairment remained poorly characterized prior to this investigation. The researchers sought to examine the expression profile of lncRNA ITGA2 in patients with acute ischemic stroke, clarify its relationship with cognitive deficits, and assess its potential for diagnosis and prognosis.
The study design involved recruiting 152 healthy individuals attending routine health check-ups and 155 patients admitted to the neurology department with a confirmed diagnosis of acute ischemic stroke according to American Heart Association/American Stroke Association criteria. Peripheral venous blood samples were collected within 24 hours of admission. Total RNA was isolated and reverse-transcribed to synthesize complementary DNA, followed by quantitative real-time PCR assays to determine the relative expression levels of lncRNA ITGA2. The study was approved by the Ethics Committee of The Second Affiliated Hospital of Hainan Medical University, and written informed consent was provided by all participants.
Baseline characteristics were compared between the healthy controls and the acute ischemic stroke patients. The analysis revealed no significant differences between the two groups regarding age, body mass index, gender, smoking history, or alcohol consumption history. Among the acute ischemic stroke patients, the rates of hypertension and diabetes were 47.1% and 48.4%, respectively. The average modified Rankin Scale score, which measures functional disability, was 2.57, and the National Institutes of Health Stroke Scale score, which assesses neurological deficit, was 7.76 in the patient group.
The results demonstrated that lncRNA ITGA2 expression was markedly elevated in patients with acute ischemic stroke relative to healthy individuals. Receiver operating characteristic curve analysis yielded an area under the curve of 0.907 for the diagnosis of acute ischemic stroke, indicating high discriminative capacity. At the optimal cutoff value of 1.273, the sensitivity and specificity for diagnosis were 83.2% and 85.5%, respectively. Furthermore, lncRNA ITGA2 expression exhibited a strong positive correlation with both the modified Rankin Scale score and the National Institutes of Health Stroke Scale score, implying that elevated expression levels are linked to more pronounced neurological impairment and poorer functional recovery.
To evaluate the prognostic value for cognitive outcomes, patients were monitored over a six-month period. Cognitive function was assessed using the Montreal Cognitive Assessment, a tool designed to identify cognitive impairment across multiple domains including attention, executive function, memory, and language. No significant differences were observed between these two groups in terms of baseline demographics or clinical characteristics, although patients with cognitive impairment demonstrated significantly higher neurological disability scores.
Comparative analyses indicated that patients with post-stroke cognitive impairment obtained significantly lower Montreal Cognitive Assessment scores than those without cognitive impairment. Simultaneously, expression levels of lncRNA ITGA2 were significantly elevated in the post-stroke cognitive impairment group compared to the cognitively normal group. Correlation analysis within the post-stroke cognitive impairment group revealed a strong negative association between lncRNA ITGA2 expression and Montreal Cognitive Assessment scores, suggesting that higher RNA levels correlate with greater severity of cognitive deficits.
Survival analysis using Kaplan-Meier curves showed that patients with high lncRNA ITGA2 expression exhibited a significantly greater cumulative incidence of cognitive impairment and an earlier time to onset compared to those with low expression. A multivariate Cox proportional hazards model, adjusted for potential confounders including age, body mass index, and comorbidities, confirmed that elevated lncRNA ITGA2 expression remained independently associated with an increased risk of cognitive impairment. The hazard ratio was 3.955, with a 95% confidence interval of 2.207 to 7.485. Receiver operating characteristic analysis for predicting post-stroke cognitive impairment yielded an area under the curve of 0.900, with a sensitivity of 86.4% and specificity of 79.7% at the optimal cutoff.
The biological rationale for these associations may be grounded in the genomic locus of lncRNA ITGA2, which may regulate its cognate protein-coding gene, ITGA2, or Integrin Subunit Alpha 2. This integrin is a crucial mediator of cell-cell and cell-matrix adhesion, with established roles in driving vascular smooth muscle proliferation and invasion, processes intimately linked to cerebral ischemia. Aberrant integrin signaling is known to facilitate the adhesion and transendothelial migration of neutrophils and monocytes, igniting neuroinflammation, while also activating platelets to fuel thrombosis. The upregulation of lncRNA ITGA2 may thus act as a marker of pathological integrin hyperactivation, exacerbating neuroinflammation and compromising the blood-brain barrier.
The study acknowledges certain limitations that must be considered when interpreting the findings. While the sample size satisfied the minimum thresholds for statistical analyses, increasing it could strengthen the reliability and broader applicability of the results. Additionally, the research was conducted at a single center, which introduces the possibility of selection bias. The observational design of the study means that while strong associations were identified, causal mechanisms require further investigation through multi-center studies with larger cohorts and mechanistic experiments.
In conclusion, peripheral lncRNA ITGA2 shows significant diagnostic value for acute ischemic stroke and serves as an independent risk factor and predictive biomarker for post-stroke cognitive impairment. Its ability to be assessed non-invasively in peripheral blood supports its potential utility as a tool for early detection and risk evaluation in clinical settings. Future studies should prioritize confirming its clinical utility and further clarifying its precise mechanisms in ischemic cerebral injury and cognitive deterioration, potentially providing a foundation for new therapeutic interventions and treatment strategies for stroke survivors.
Methodological specifics regarding participant screening and laboratory validation provided rigor to the clinical evaluation. To prevent confounding from prior neurological deficits, investigators excluded candidates exhibiting pre-existing dementia or cognitive decline, defined by a Mini-Mental State Examination score below 24, as well as individuals presenting with severe aphasia, altered consciousness, active infections, or malignant tumors. The study cohort size was determined using G*Power software, securing an analytical power of 99 percent at an alpha level of 0.05. Laboratory quantification from the three-milliliter peripheral venous samples utilized the PAXgene Blood RNA Kit and PrimeScript RT Reagent Kit. Crucially, the stability of candidate reference genes was evaluated using the geNorm and NormFinder algorithms; GAPDH achieved the lowest geNorm M value of 0.35, confirming its optimal stability as the endogenous normalizer for calculating relative expression through the comparative cycle threshold method.
The longitudinal cognitive monitoring framework also incorporated strict diagnostic criteria across multiple neurological domains. Cognitive assessments conducted six months post-stroke evaluated attention, executive function, memory, language skills, visuospatial abilities, abstract reasoning, calculation, and orientation within a 30-point scale. Participants scoring greater than 26 were classified as possessing normal cognition, whereas scores between 18 and 26 indicated mild impairment, 10 to 17 marked moderate deficits, and values below 10 denoted severe impairment. Tracking these thresholds over the follow-up period established that 81 acute ischemic stroke patients developed cognitive impairment, while 74 maintained normal cognitive function. In statistical modeling, the predictive separation demonstrated a 95 percent confidence interval between 0.853 and 0.947 for the cognitive impairment area under the curve, corroborating the clinical precision of peripheral transcript levels during acute recovery.
At the molecular level, these clinical associations align with broader regulatory networks identified in cerebrovascular pathology. Researchers note that lncRNA ITGA2 interacts functionally with the DNA-binding protein NONO, altering chromatin organization within vascular smooth muscle cells. Because NONO has independently been implicated in mediating neuroinflammatory signaling cascades during neurodegenerative diseases, this interaction highlights a plausible pathway linking vascular remodeling to central nervous system damage. Similar patterns appear across related non-coding transcripts, including lncRNA-U90926, which modulates microglial activation, and lncRNA SNHG3, which influences inflammatory damage following cerebral ischemia-reperfusion injury. Together, these observations suggest that altered expression of circulating lncRNA ITGA2 reflects intricate cellular processes that worsen barrier integrity and accelerate secondary cognitive decline.
Subject of Research: LncRNA ITGA2 as a Novel Diagnostic and Prognostic Biomarker for Post-Stroke Cognitive Impairment: A Clinical Investigation
Article Title: LncRNA ITGA2 as a Novel Diagnostic and Prognostic Biomarker for Post-Stroke Cognitive Impairment: A Clinical Investigation
Article References: Chen, L., Zeng, C., Xing, H., Chen, M., & Yan, L. (2026). LncRNA ITGA2 as a Novel Diagnostic and Prognostic Biomarker for Post-Stroke Cognitive Impairment: A Clinical Investigation. Artery Research, 32(1), Article 10. https://doi.org/10.1007/s44200-026-00111-4
Image Credits: AI Generated
DOI: 10.1007/s44200-026-00111-4
Keywords: LncRNA, ITGA2, Novel, Diagnostic, Prognostic, Biomarker, Post-Stroke, Cognitive, Impairment, Clinical, Investigation, scientific research
News Source: Cassandra Pierce. (November 10, 2026). Blood RNA Marker Predicts Cognitive Decline After Stroke. Scienmag.
